Man Yee Mallory Leung1, Nils P Carlsson1, Graham A Colditz1, Su-Hsin Chang2. 1. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA. 2. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA. Electronic address: changsh@wudosis.wustl.edu.
Abstract
BACKGROUND: Diabetes is one of the most prevalent and costly chronic diseases in the United States. OBJECTIVES: To analyze the risk of developing diabetes and the annual cost of diabetes for a US general population. METHODS: Data from the Medical Expenditure Panel Survey, 2008 to 2012, were used to analyze 1) probabilities of developing diabetes and 2) annual total health care expenditures for diabetics. The age-, sex-, race-, and body mass index (BMI)-specific risks of developing diabetes were estimated by fitting an exponential survival function to age at first diabetes diagnosis. Annual health care expenditures were estimated using a generalized linear model with log-link and gamma variance function. Complex sampling designs in the Medical Expenditure Panel Survey were adjusted for. All dollar values are presented in 2012 US dollars. RESULTS: We observed a more than 6 times increase in diabetes risks for class III obese (BMI ≥ 40 kg/m2) individuals compared with normal-weight individuals. Using age 50 years as an example, we found a more than 3 times increase in annual health care expenditures for those with diabetes ($13,581) compared with those without diabetes ($3,954). Compared with normal-weight (18.5 ≤ BMI < 25 kg/m2) individuals, class II obese (35 ≤ BMI < 40 kg/m2) and class III obese (BMI ≥ 40 kg/m2) individuals incurred an annual marginal cost of $628 and $756, respectively. The annual health care expenditure differentials between those with and without diabetes of age 50 years were the highest for individuals with class II ($12,907) and class III ($9,703) obesity. CONCLUSIONS: This article highlights the importance of obesity on diabetes burden. Our results suggested that obesity, in particular, class II and class III (i.e., BMI ≥ 35 kg/m2) obesity, is associated with a substantial increase in the risk of developing diabetes and imposes a large economic burden.
BACKGROUND:Diabetes is one of the most prevalent and costly chronic diseases in the United States. OBJECTIVES: To analyze the risk of developing diabetes and the annual cost of diabetes for a US general population. METHODS: Data from the Medical Expenditure Panel Survey, 2008 to 2012, were used to analyze 1) probabilities of developing diabetes and 2) annual total health care expenditures for diabetics. The age-, sex-, race-, and body mass index (BMI)-specific risks of developing diabetes were estimated by fitting an exponential survival function to age at first diabetes diagnosis. Annual health care expenditures were estimated using a generalized linear model with log-link and gamma variance function. Complex sampling designs in the Medical Expenditure Panel Survey were adjusted for. All dollar values are presented in 2012 US dollars. RESULTS: We observed a more than 6 times increase in diabetes risks for class III obese (BMI ≥ 40 kg/m2) individuals compared with normal-weight individuals. Using age 50 years as an example, we found a more than 3 times increase in annual health care expenditures for those with diabetes ($13,581) compared with those without diabetes ($3,954). Compared with normal-weight (18.5 ≤ BMI < 25 kg/m2) individuals, class II obese (35 ≤ BMI < 40 kg/m2) and class III obese (BMI ≥ 40 kg/m2) individuals incurred an annual marginal cost of $628 and $756, respectively. The annual health care expenditure differentials between those with and without diabetes of age 50 years were the highest for individuals with class II ($12,907) and class III ($9,703) obesity. CONCLUSIONS: This article highlights the importance of obesity on diabetes burden. Our results suggested that obesity, in particular, class II and class III (i.e., BMI ≥ 35 kg/m2) obesity, is associated with a substantial increase in the risk of developing diabetes and imposes a large economic burden.
Authors: M E Martínez; T Maltzman; J R Marshall; J Einspahr; M E Reid; R Sampliner; D J Ahnen; S R Hamilton; D S Alberts Journal: Cancer Res Date: 1999-10-15 Impact factor: 12.701
Authors: M J Gil; M A Mañú; C Arteaga; M Migliaccio; I Encío; A González; V Martínez-Merino Journal: Bioorg Med Chem Lett Date: 1999-08-16 Impact factor: 2.823
Authors: Joan M O'Connell; Jennifer E Rockell; Judith C Ouellet; Sherri Yoder; Kimberly E Lind; Charlton Wilson; Andrew Friedson; Spero M Manson Journal: EC Endocrinol Metab Res Date: 2021-01-27
Authors: Owen T Carmichael; Rebecca H Neiberg; Gareth R Dutton; Kathleen M Hayden; Edward Horton; F Xavier Pi-Sunyer; Karen C Johnson; Stephen R Rapp; Adam P Spira; Mark A Espeland Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958
Authors: Rachel G Tabak; Jaime R Strickland; Richard I Stein; Hank Dart; Graham A Colditz; Bridget Kirk; Ann Marie Dale; Bradley A Evanoff Journal: BMC Public Health Date: 2018-11-16 Impact factor: 3.295